GlobeStar Therapeutics Corp (GSTC)

[ten_percent_or_more]

AngioSoma, Inc. Welcomes Dr. Tom Garcia to Scientific Advisory Board

July 28, 2016 01:00 PM Eastern Daylight Time
MONTGOMERY, Texas--(BUSINESS WIRE)--AngioSoma, Inc. (OTCQB:SOAN) (the 'Company,' 'we,' and 'our'), announces the formation of its scientific advisory board with the addition of A. Tomas Garcia III, MD, a practicing physician in the field of cardiology for the past 35 years and the immediate past president of the Texas Medical Association. Dr. Garcia's longstanding association with our Chairman Emeritus and insight into the Company's flagship product Liprostin™ allows Dr. Garcia to immediately make a significant impact on our progress towards U.S. Food and Drug Administration ('FDA') Phase III trials of Liprostin™.

“Liprostin™ is an important step towards helping many patients in my field, and I am pleased to make an impact on AngioSoma's progress towards its completion of FDA trials”
Tweet this
“Liprostin™ is an important step towards helping many patients in my field, and I am pleased to make an impact on AngioSoma's progress towards its completion of FDA trials,” Dr. Garcia remarked. “Having Dr. Garcia lead our scientific advisory board brings knowledge of the whole FDA process that increases our odds of successful FDA trials and eventual FDA approval of Liprostin™,” Chairman Emeritus David 'Doc' Summers, PhD, added.

ABOUT ANGIOSOMA, INC.

AngioSoma, Inc. (http://www.angiosoma.com) is a clinical stage biopharmaceutical company focused on improving the effectiveness of current standard-of-care treatments, especially related to endovascular interventions in the treatment of peripheral artery disease ('PAD'). Our lead pharmaceutical product Liprostin™, a treatment for PAD, has successfully completed FDA Phase I and three Phase II clinical trials, and we are in discussions with several contract research organizations for rapid completion of our U.S. Food and Drug Administration ('FDA') approved protocol for Phase III with submission of our new drug application for marketing in the U.S. and its territories.

NOTICE REGARDING FORWARD LOOKING STATEMENTS

This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements that include the words “believes,” “expects,” “anticipate” or similar expressions. Such forward-looking statements involve known and unknown risks, and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone’s past success is no guarantee of future success. This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof.

Contacts
AngioSoma, Inc.
Alex Blankenship, 832-781-8521
[e-mail]

ANGIOSOMA, INC.
OTCQB:SOAN View stock quote and chart View SEC Filings
Release Versions
English EON: Enhanced Online News
More NewsRSS feed for AngioSoma, Inc